Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 100

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 100
---
 loan in the total amount of $200,000 pursuant to the 2025 Loan Agreements; and (vi) the  
 expiration of certain outstanding warrants to purchase up to 167,365 Ordinary Shares in March 2025.                                 |

| ● | on a pro forma as                                                                                                                    
 adjusted basis to give further effect to: (i) the sale of 909,090 Ordinary Shares in this offering at an initial public              
 offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this            
 prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us; (ii) repayment of  
 the Bridge Loan in the total amount of $350,000 plus accrued interest and an aggregate risk premium in the amount of $105,000; (iii) 
 the repayment of the loan under the 2024 Loan Agreements in the total amount of $150,000 plus accrued interest and an aggregate risk 
 premium in the amount of $50,000; (iv) the repayment of the loan under the December 2024 Loan Agreement in the total amount of       
 $117,000 plus accrued interest and an aggregate risk premium of approximately $35,100; and (v) the repayment of the loan under the   
 2025 Loan Agreements in the total amount of $200,000 plus accrued interest and an aggregate risk premium in the                      
 amount of $100,000;                                                                                                                  |

The pro forma as adjusted
information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other
terms of this offering determined at pricing.

You should read this table
in conjunction with the sections titled “Use of Proceeds”, “Selected Financial Data”, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included
elsewhere in this prospectus.

|                                 |     | As of December 31, 2024 |         |   |     |           |        |   |     |                |       |
|:--------------------------------|:----|:------------------------|--------:|:--|:----|:----------|-------:|:--|:----|:---------------|------:|
| U.S. dollars in thousands       |     | Actual                  |         |   |     | Pro Forma |        |   |     | Pro            
 Forma          
 As Adjusted(1) |       |
|